Drug Profile
Research programme: antiemetic and antinauseant therapeutic - Sumitomo Pharma/Maruishi Pharmaceutical
Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Sumitomo Dainippon Pharma
- Developer Maruishi Pharmaceutical; Sumitomo Pharma
- Class
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Nausea and vomiting